ClinicalTrials.gg
CompletedNCT01824290Updated Nov 5, 2021Results posted

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Tadalafil and Placebo in Hypertension, Pulmonary, sponsored by Eli Lilly and Company. Completed at 43 sites in 14 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.

Enrollment
10th of 18
35 · median 40
Started
2014
the only one that year
Phase 3
8 of 18
2 open now
Registered
10th of 18
by date
Lead sponsor
3 of 18
Eli Lilly and Company

Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 3, and was the 10th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing tadalafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.

03

Conditions studied

  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥6 months to \<18 years of age at screening
  • Currently have a diagnosis of PAH that is either:

    • idiopathic, including hereditary
    • related to connective tissue disease
    • related to anorexigen use
    • associated with surgical repair of at least 6-month duration of congenital systemic to pulmonary shunt (eg, atrial septal defect, ventricular septal defect, patent ductus arteriosus)
  • Have a history of a diagnosis of PAH established by a resting mean pulmonary artery pressure (mPAP) ≥25 millimeter of mercury (mm Hg), pulmonary artery wedge pressure ≤15 mm Hg, and a pulmonary vascular resistance (PVR) ≥3 Wood units via right heart catheterization (RHC). In the event that a pulmonary artery wedge pressure cannot be obtained during RHC, participants with a left ventricular end diastolic pressure (LVEDP) \<15 mm Hg, with normal left heart function, and absence of mitral stenosis on echocardiography can be eligible for enrollment
  • Have a World Health Organization (WHO) functional class value of II or III at the time of screening
  • All participants must be receiving an endothelin receptor antagonist (ERA) (such as bosentan or ambrisentan) and must be on a maintenance dose with no change in dose (other than weight-based adjustments) for at least 12 weeks prior to screening and have a screening (AST)/alanine transaminase (ALT) \<3 times the (ULN)
  • If on conventional PAH medication, including but not restricted to, anticoagulants, diuretics, digoxin, and oxygen therapy, the participant must be on stable doses with no changes (other than weight-based adjustments) for at least 4 weeks before screening
  • Female participants of must test negative for pregnancy during screening. Furthermore, female participants must agree to abstain from sexual activity or to use two different reliable methods of as determined by the Investigator during the study. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices)
  • Written from parents (and written assent from appropriately aged participants) will be obtained prior to any study procedure being performed

Exclusion criteria

Exclusion Criteria:

  • Have pulmonary hypertension related to conditions other than specified above, including but not limited to chronic thromboembolic disease, portal pulmonary hypertension, left-sided heart disease or lung disease and hypoxia
  • History of left-sided heart disease, including any of the following:

    • [pulmonary artery occlusion pressure (PAOP) 15-18 mm Hg] aortic or mitral valve disease (ie, aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation)
    • pericardial constriction
    • restrictive or congestive cardiomyopathy
    • \<40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography
    • left ventricular shortening fraction \<22% by echocardiography
    • life-threatening cardiac arrhythmias
    • symptomatic coronary artery disease within 5 years of study entry
  • Unrepaired congenital heart disease
  • Have a history of angina pectoris or other condition that was treated with long- or short-acting nitrates within 12 weeks before administration of study drug
  • Have severe hepatic impairment, Grade C
  • Have severe renal insufficiency, defined as receiving renal dialysis or having a measured or estimated (CC) \<30 millimeter per minute (mL/min) (Schwartz Formula)
  • Diagnosed with a retinal disorder (eg, hereditary retinal disorders, retinopathy of the preterm participant and other retinal disorders)
  • Have severe hypotension or uncontrolled hypertension as determined by the Investigator
  • Have significant parenchymal lung disease
  • Have bronchopulmonary dysplasia
  • Concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy (sildenafil or vardenafil) or has received PDE5 inhibitor therapy within 12 weeks prior to the first study drug dosing
  • Concurrent therapy with prostacyclin or its analogues within 12 weeks of screening
  • Commenced or discontinued a chronic conventional PAH medication including but not restricted to: diuretics, anti-coagulants, digoxin, and oxygen therapy within 4 weeks of screening
  • Currently receiving treatment with doxazosin, nitrates, or cancer therapy
  • Current treatment with potent Cytochrome P450 3A4 () inhibitors, such as antiretroviral therapy (protease inhibitor), systemic ketoconazole, or systemic itraconazole, or chronic use of potent CYP3A4 inducers, such as rifampicin
  • Are nursing or pregnant
  • Have previously completed or withdrawn from this study (LVHV), or any other study investigating tadalafil
  • Have received tadalafil therapy within 12 weeks prior to the first study drug dosing or are hypersensitive to tadalafil
  • Have allergy to the , notably lactose
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study by the Sponsor
  • Unable to take orally administered tablets (without chewing, crushing or breaking) or suspension
  • Are Investigator site personnel directly affiliated with this study or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
  • Diagnosis of Down syndrome
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Period 1: 20 mg or 40 mg administered orally by tablets once a day. Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day. Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to \<40 kg: administered orally by tablets once a day. Light weight cohort \<25 kg: administered orally by suspension once a day. Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension).

    Drug: Tadalafil · Drug: ERA as specific PAH treatment

  • Placebo comparator
    Placebo

    Period 1: Participants received placebo orally by tablets once a day. Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day. Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort. Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group.

    Drug: Placebo · Drug: ERA as specific PAH treatment

Interventions

  • Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.

    Also known as: LY450190, Cialis, Adcirca, IC351

  • DrugPlacebo

    Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.

  • DrugERA as specific PAH treatment

    All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).

06

What researchers measure

Primary outcomes

  1. Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters

    6MWD in meters assessed in a subset of participants who are ≥6 to \<18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Period 1: Time to Adjudicated Clinical Worsening (CW)

    Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.

    Time frame: Baseline through Week 24

  2. Period 1: Percentage of Participants Who Experience CW

    Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.

    Time frame: Baseline through Week 24

  3. Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state

    Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state

    Time frame: Week 2, Week 4, Week 16 and Week 24

  4. Period 2: Percentage of Participants Who Experience CW

    Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

    Time frame: Period 2 Baseline through Study Completion (Up to 24 Months)

  5. Period 2: Time to First Occurrence of CW

    Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

    Time frame: Period 2 Baseline through Study Completion (Up to 24 Months)

07

Results

Posted Mar 23, 2020
Limitations and caveats
The study is mainly descriptive in a small number of children with PAH and there were no participants enrolled in the light weight cohort.

Participant flow

Period 1: Double Blind
Participant flow — Period 1: Double Blind
MilestonePlaceboTadalafilPlacebo/TadalafilTadalafil/Tadalafil
Started181700
Received at least one dose of study drug181700
Received 20 mg0400
Received 40 mg01300
Completed151500
Not completed3200
Withdrew: Entry criteria not met1000
Withdrew: Parent/caregiver decision1100
Withdrew: Investigator reported clinical worsening1100
Period 2: Open-Label Treatment
Participant flow — Period 2: Open-Label Treatment
MilestonePlaceboTadalafilPlacebo/TadalafilTadalafil/Tadalafil
Started001616
Received 20 mg0033
Received 40 mg001313
Completed001313
Not completed0033
Withdrew: Adverse event0001
Withdrew: Parent/caregiver decision0011
Withdrew: Withdrawal by subject0021

Outcome measures

PrimaryPeriod 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters

6MWD in meters assessed in a subset of participants who are ≥6 to \<18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Meters
Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters
MetersPlaceboTadalafil
Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters36.60 ± 20.77660.48 ± 20.410
Statistical analysis
  • Placebo vs Tadalafil · Mean difference (final values): 23.88 · 80% CI -14.25 to 62.00
SecondaryPeriod 1: Time to Adjudicated Clinical Worsening (CW)

Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.

Time frame:
Baseline through Week 24
Reported as:
Median · Weeks
Period 1: Time to Adjudicated Clinical Worsening (CW)
WeeksPlaceboTadalafil
Period 1: Time to Adjudicated Clinical Worsening (CW)NA (NA to NA)NA (NA to NA)
SecondaryPeriod 1: Percentage of Participants Who Experience CW

Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance(for those participants who are ≥6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment.

Time frame:
Baseline through Week 24
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Who Experience CW
percentage of participantsPlaceboTadalafil
Period 1: Percentage of Participants Who Experience CW00
SecondaryPeriod 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state

Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state

Time frame:
Week 2, Week 4, Week 16 and Week 24
Reported as:
Geometric mean · Liter Per Hour (L/hr)
Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state
Liter Per Hour (L/hr)20 mg Tadalafil40 mg Tadalafil
With concomitant bosentan3.63 ± 38.14.49 ± 28.2
No bosentan (ERA: Macitentan)NA ± NA—
SecondaryPeriod 2: Percentage of Participants Who Experience CW

Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

Time frame:
Period 2 Baseline through Study Completion (Up to 24 Months)
Reported as:
Number · percentage of participants
Period 2: Percentage of Participants Who Experience CW
percentage of participantsPlacebo/Tadalafil - Open-Label TreatmentTadalafil/Tadalafil - Open-Label Treatment
Period 2: Percentage of Participants Who Experience CW12.518.8
SecondaryPeriod 2: Time to First Occurrence of CW

Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

Time frame:
Period 2 Baseline through Study Completion (Up to 24 Months)
Reported as:
Median · Months
Period 2: Time to First Occurrence of CW
MonthsPlacebo/Tadalafil - Open-Label TreatmentTadalafil/Tadalafil - Open-Label Treatment
Period 2: Time to First Occurrence of CWNA (NA to NA)NA (NA to NA)

Adverse events

Collected over Baseline Up To 24 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Double Blind0/18 (0%)0/18 (0%)8/18 (44.4%)
Tadalafil - Double Blind0/17 (0%)0/17 (0%)15/17 (88.2%)
Placebo/Tadalafil - Open-Label Treatment0/16 (0%)4/16 (25%)11/16 (68.8%)
Tadalafil/Tadalafil - Open-Label Treatment0/16 (0%)1/16 (6.3%)12/16 (75%)
Most frequent serious events
Most frequent serious events
EventPlacebo - Double BlindTadalafil - Double BlindPlacebo/Tadalafil - Open-Label TreatmentTadalafil/Tadalafil - Open-Label Treatment
AnaemiaBlood and lymphatic system disorders0/180/171/160/16
Acute right ventricular failureCardiac disorders0/180/170/161/16
GastroenteritisInfections and infestations0/180/171/160/16
PneumoniaInfections and infestations0/180/171/160/16
HaemoptysisRespiratory, thoracic and mediastinal disorders0/180/171/160/16
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPlacebo - Double BlindTadalafil - Double BlindPlacebo/Tadalafil - Open-Label TreatmentTadalafil/Tadalafil - Open-Label Treatment
HeadacheNervous system disorders2/185/172/163/16
VomitingGastrointestinal disorders0/180/170/163/16
NasopharyngitisInfections and infestations0/180/171/163/16
DizzinessNervous system disorders0/180/171/163/16
InfluenzaInfections and infestations0/183/170/161/16
Upper respiratory tract infectionInfections and infestations1/183/170/162/16
Penis disorderReproductive system and breast disorders0/91/70/80/6
Spontaneous penile erectionReproductive system and breast disorders0/91/71/80/6
AnaemiaBlood and lymphatic system disorders0/180/172/160/16
Abdominal pain upperGastrointestinal disorders0/180/170/162/16

Baseline characteristics

All participants who received at least one dose of study drug. Per protocol and statistical analysis plan (SAP), the primary and secondary analysis were performed to compare all tadalafil participants together versus all placebo participants together.

Age, Continuous
Age, Continuous(years)PlaceboTadalafilTotal
Mean12.8 ± 3.3914.1 ± 3.4913.5 ± 3.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female91019
Male9716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTadalafilTotal
Hispanic or Latino7815
Not Hispanic or Latino6410
Unknown or Not Reported5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTadalafilTotal
American Indian or Alaska Native134
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American213
White141226
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboTadalafilTotal
Japan112
Turkey213
Brazil9615
Mexico145
Israel246
France112
Germany101
Poland101
6 Minute Walk Distance
6 Minute Walk Distance(Meters)PlaceboTadalafilTotal
Mean476.7 ± 105.11485.8 ± 160.231481.1 ± 132.77
08

Study locations

43 sites
  • Children's Heathcare of Atlanta, Inc. at Egleston
    Atlanta, Georgia 30322, United States
  • Childrens Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hosp
    Columbus, Ohio 43205-2664, United States
  • Vanderbilt Univeristy School of Medicine
    Nashville, Tennessee 37212-2372, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Primary Childrens Medical Center
    Salt Lake City, Utah 84132, United States
  • AKH
    Wien, 1090, Austria
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Pronto Socorro Cardiologico de Pernambuco-PROCAPE
    Recife, PE 50100-060, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90020-090, Brazil
  • Instituto Dante Pazzanese de Cardiologia
    Sao Paulo, SP 04012-180, Brazil
  • UNIFESP - Escola Paulista de Medicina
    Sao Paulo, SP 04037-002, Brazil
  • CHU Hopital d'enfants de la Timone
    Marseille Cedex 05, 13385, France
  • GH Necker - Enfants Malades
    Paris Cedex 15, 75743, France
  • Hopital Haut Leveque - Group hospitalier Sud
    Pessac, 33604, France
  • Chu de Toulouse - Hopital des Enfants
    Toulouse Cedex 3, 31026, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Universitätsklinikum Ulm
    Ulm, Baden-Württemberg 89075, Germany
  • Sheba Medical Center
    Tel Hashomer, Ramat Gan 5265601, Israel
  • Schneider Medical Center
    Petah Tiqva, 4920235, Israel
  • Istituto Giannina Gaslini Ospedale Pediatrico I.R.C.C.S.
    Genova, GE 16147, Italy
  • Ospedale V. Monaldi
    Napoli, 80131, Italy
  • Ospedale Bambino Gesu
    Roma, 00165, Italy
  • Gunma Children's Medical Center
    Shibukawa, Gunma 377-8577, Japan
  • Asahikawa Medical College Hospital
    Asahikawa, Hokkaido 078-8510, Japan
  • Mie University Hospital
    Tsu, Mie 514-8507, Japan
  • Okinawa Prefectural Nanbu Medical Center & Children's Med Ct
    Haebaru-cho, Shimajiri-gun, Okinawa 901-1193, Japan
  • Tokyo Metropolitan Children's Medical Center
    Fuchu, Tokyo 183-8561, Japan
  • Toho University Omori Medical Center
    Ohta-Ku, Tokyo 143-8541, Japan
  • National Center For Child Health And Development
    Setagaya-ku, Tokyo 157-8535, Japan
  • Shizuoka Prefectural Children's Hospital
    Shizuoka, 420-8660, Japan
  • Instituto Nacional de Cardiologia Ignacio Chavez
    Ciudad de Mexico, DF 14080, Mexico
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Instytut Pomnik-Centrum Zdrowia Dziecka
    Warszawa, Woj Mazowieckie 04-730, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Uniwersytecki Szpital Dzieciecy w Krakowie-Prokocimiu
    Krakow, 30-633, Poland
  • Wojewódzki Szpital Specjalistyczny we Wrocławiu
    Wroclaw, 51-124, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hacettepe University Faculty of Medicine
    Ankara, 06100, Turkey
  • Gazi University Medical Faculty
    Besevler/Ankara, 06500, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Mar 2019, 61 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
Apr 4, 2013
StartActual
Feb 5, 2014
Primary completionActual
Mar 18, 2019
CompletionActual
Mar 10, 2021
Results first posted
Mar 23, 2020
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01824290
Responsible party
Sponsor
First posted
Apr 4, 2013
Start date
Feb 5, 2014
Primary completion
Mar 18, 2019
Completion
Mar 10, 2021
Results posted
Mar 23, 2020
Last update
Nov 5, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion